Flutamide-induced regression of angiofibroma.

Abstract

Juvenile nasopharyngeal angiofibroma (JNA) appears to be an endocrine-responsive tumor. This concept was tested in five young men with JNA by treating them with a testosterone receptor blocker (flutamide) for 6 weeks preoperatively. Tumor size was evaluated by axial computed tomography both before and after flutamide therapy. Four of the five patients had an average tumor shrinkage of 44%. The patients tolerated the drug well, and the serum testosterone levels 2 or more years posttherapy were normal. This pilot study demonstrate that preoperative hormonal pharmacoreduction of JNA is a feasible adjunct to surgical therapy that offers the possibility of reduced blood loss. However, the authors believe that a formal clinical trial of this treatment approach is warranted and should be done before widespread adoption of this agent.

• Authors: G A Gates, D H Rice, C F Koopmann Jr, D E Schuller
• Journal: The Laryngoscope (Laryngoscope) Vol. 102 Issue 6 Pg. 641-4 (Jun 1992) ISSN: 0023-852X [Print] United States
• PMID: 1318484 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Receptors, Androgen
• Testosterone
• Flutamide

Topics

• Adolescent
• Chemotherapy, Adjuvant
• Flutamide (therapeutic use)
• Follow-Up Studies
• Histiocytoma, Benign Fibrous (chemistry, drug therapy, pathology, surgery)
• Humans
• Male
• Nasopharyngeal Neoplasms (chemistry, drug therapy, pathology, surgery)
• Neoplasm Staging
• Pilot Projects
• Premedication
• Receptors, Androgen (analysis)
• Remission Induction
• Testosterone (analysis)